1. Home
  2. WTI vs NGNE Comparison

WTI vs NGNE Comparison

Compare WTI & NGNE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo W&T Offshore Inc.

WTI

W&T Offshore Inc.

N/A

Current Price

$3.46

Market Cap

309.5M

Sector

Energy

ML Signal

N/A

Logo Neurogene Inc.

NGNE

Neurogene Inc.

N/A

Current Price

$22.30

Market Cap

327.8M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
WTI
NGNE
Founded
1983
2003
Country
United States
United States
Employees
N/A
N/A
Industry
Oil & Gas Production
Biotechnology: Pharmaceutical Preparations
Sector
Energy
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
309.5M
327.8M
IPO Year
2004
2014

Fundamental Metrics

Financial Performance
Metric
WTI
NGNE
Price
$3.46
$22.30
Analyst Decision
Strong Buy
Analyst Count
0
8
Target Price
N/A
$60.13
AVG Volume (30 Days)
5.8M
157.3K
Earning Date
01-01-0001
01-01-0001
Dividend Yield
1.40%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$487,096,000.00
$925,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
$0.73
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$1.09
$6.88
52 Week High
$3.82
$37.27

Technical Indicators

Market Signals
Indicator
WTI
NGNE
Relative Strength Index (RSI) 67.13 56.11
Support Level $1.71 $19.44
Resistance Level N/A $25.79
Average True Range (ATR) 0.30 2.28
MACD 0.02 0.24
Stochastic Oscillator 72.34 51.91

Price Performance

Historical Comparison
WTI
NGNE

About WTI W&T Offshore Inc.

W&T Offshore Inc is an oil and gas exploration and production company. The company's exploration operations are focused in the Gulf of Mexico, where it drills for oil and gas. The company engages in both deepwater drilling and shallow-water shelf drilling. W&T Offshore extracts crude oil, natural gas, and natural gas liquids, which are then sold directly at the wellhead. Overall, crude oil accounts for the majority of company's revenue, with natural gas accounting for a much smaller portion.

About NGNE Neurogene Inc.

Neurogene Inc is a clinical-stage biotechnology company committed to overcoming the limitations of neurological diseases into treatable conditions, by harnessing its proprietary transgene regulation technology, EXACTTM (Expression Attenuation via Construct Tuning). It is building a differentiated product portfolio of genetic medicines for rare neurological diseases with high unmet needs. The drug candidates in the company's product pipeline include NGN-401, which is in development for the treatment of Rett syndrome, using its EXACT platform, and NGN-101, a non-EXACT, conventional gene therapy development candidate for the treatment of CLN5 Batten disease, designed to deliver the CLN5 gene and packaged in an AAV9 capsid.

Share on Social Networks: